Business Wire

DEXLEVO First in Asia to Win BEST Injectable Award at AMWC, the World's Largest Congress for Aesthetic Anti-aging

12.5.2022 05:29:00 EEST | Business Wire | Press release

Share

The aesthetic and medical device company DEXLEVO attended the 20th AMWC (Aesthetic & Anti-aging Medicine World Congress) held in Monaco and explained its products to the visitors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220502005974/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The aesthetic and medical device company DEXLEVO attended the 20th AMWC (Aesthetic & Anti-aging Medicine World Congress) held in Monaco and explained its products to the visitors. (Photo: Business Wire)

The world's first fully liquid PCL (polycaprolactone) injectable, GOURI developed by DEXLEVO, an aesthetic and medical device company, was the first in Asia to be chosen as Best Injectable in the category at the 20th AMWC (Aesthetic & Anti-aging Medicine World Congress) held in Monaco from March 31 to April 2, 2022.

AMWC is one of the world's most prestigious aesthetic and anti-aging congresses. More than 20,000 visitors from more than 200 countries worldwide, including dermatologists, attend the event every year to share the latest trends in aesthetic and anti-aging products and industry trends.

DEXLEVO launched GOURI, the world's first fully liquid PCL injectable, at the AMWC in 2021. Attending AMWC for the second year, it won the Best Injectable award for the first time as an Asian company at the AMWC Awards, having its unique technology and products recognized on the world stage. For the AMWC Awards, the AMWC Committee reviews and chooses the candidate products, judged by votes from dermatologists and industry workers around the world. At this year's review, DEXLEVO was nominated alongside prominent global beauty companies such as Allergan, Merz, Fillmed, and Aptos, proving its competence in the global market.

More than 150 doctors and companies visited DEXLEVO's booth and showed great interest in GOURI, which provides a fundamental solution to anti-aging.

Under the theme of "1st Liquid PCL-What, When, Why?", Mexican dermatologist Dr. Arturo Vela said, "The beauty market now wants naturalness. DEXLEVO's GOURI is the world's first fully liquid PCL injectable and the safest anti-aging product that meets consumer needs." Croatian dermatologist Dr. Dinko Kaliterna gave a treatment lecture at the congress under the theme "Skin Rejuvenation with Liquid PCL," saying, "GOURI is safer than competing products and its treatment is very convenient. Also, patient’s satisfaction with the procedure is high due to the natural collagen regeneration effect."

An official from DEXLEVO said, "As the trend in the beauty market changes, more companies are showing interest compared to last year's AMWC. Since the global market is showing increasing interest in GOURI, we plan to support marketing to become a leader in anti-aging products."

DEXLEVO's GOURI is the world's first fully liquid type PCL injectable of polycaprolactone (PCL), a biodegradable polymer material, that spreads naturally throughout the face and around the eyes when injected into the skin, forming a three-dimensional matrix and causing collagen production.

With the launch of AMWC in September 2021, DEXLEVO is selling and contracting GOURI in more than 40 countries and will participate as a platinum sponsor in IMCAS 2022, to be held in Paris in June this year, to accelerate marketing activities and expand the global market.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

DEXLEVO
Marketing Department
Chris Jeong
chrisjeong@dexlevo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences23.9.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, will present 19 abstracts and deliver a broad scientific education program at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. Through these activities, Galderma will showcase how it continues to advance its pipeline and the science of dermatology, deepening understanding of biological and quality-of-life factors, while driving innovation in targeted treatments, skin longevity and evidence-based care. “At Galderma, we recognize that advancing dermatology means not only addressing the needs of patients living with common chronic skin conditions, such as atopic dermatitis and acne, but also anticipating the trends that will shape the future of skin health. Our presence at EADV demonstrates our unique ability to achieve this, with new data spanning both established areas of unmet need and emerging fields such as skin longevity, helping drive innovation and meaningful outcomes for patients today and i

Oticon Medical Launches SmartCharger for the Ponto 5 Family23.9.2026 08:00:00 EEST | Press release

Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922863462/en/ Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. Powering the Ponto 5 family The launch of SmartCharger underlines Oticon Medical’s continued commitment to the Ponto family, which includes Ponto 5 SuperPower, the world’s most powerful abutment-level sound processor,1 and Ponto 5 Mini, the world’s smallest percutaneous sound processor.1 By bringing rechargeable convenience to the Ponto sound processors, Oticon Me

Textron Aviation Marks 500th Cessna Citation Latitude Rollout22.9.2026 17:19:00 EEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the rollout of the 500th Cessna Citation Latitude business jet from the company’s Wichita, Kansas, manufacturing facility. The production milestone highlights the continued success of the world’s best-selling midsize business jet and recognizes the employees whose craftsmanship and dedication have helped make the Citation Latitude the trusted choice for operators around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922867287/en/ Textron Aviation marks 500th Cessna Citation Latitude rollout. (Photo Credit: Textron Aviation) “The rollout of the 500th Citation Latitude is a testament to the employees who build this aircraft with dedication and pride every day,” said Eric Cardinali, senior vice president, Manufacturing. “Behind every aircraft is a team committed to delivering the quality and craftsmanship our customers expect. This milestone

OCP Announces Date of Second Quarter and First Half 2026 Earnings22.9.2026 17:00:00 EEST | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. EDT, 2:00 p.m. Morocco (GMT) and 3:00 p.m. London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2026 results at 11:00 a.m. EDT, 3:00 p.m. Morocco (GMT) and 4:00 p.m. London time (GMT+1) on Tuesday, September 29, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 16:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be shared at the congress. “Takeda’s data at ESMO reflect our commitment to delivering rapid progress for patients living with some of the most prevalent and challenging cancers, including advanced gastric cancer and immunotherapy-resistant and previously untreated non-small cell lung cancer,” said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit at Takeda. “Our mission is to advance new therapeutic approaches for patients who need more options or who remain underserved by cur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye